Tests activated charcoal against phosphate binders in people on dialysis
Tests activated charcoal to lower high phosphate in adults on dialysis for kidney failure.
Plain-language title generated from the registry record
Registry title: Activated Charcoal Use in Chronic Kidney Disease Patients
Key facts
- Where
- Al Mansurah, EgyptSee the site
- Phase
- Phase 2
Where in Egypt
- Urology and Nephrology CenterAl Mansurah, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mansoura University
- Trial code
- NCT06906874
- Record updated
- 8 August 2025
- Original description
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.Read full original descriptionShow less
Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.
Inclusion: Adult aged ≥18 years with ESRD; Patients who had been on stable maintenance hemodialysis (3 times weekly) for at least 6 months; Patients receiving phosphate binders according to standard protocols established by kidney disease: Improving Global Outcomes (KDIGO).
Exclusion: Treated with overnight dialysis; Primary hyperparathyroidism or persistent serum levels of intact parathyroid hormone greater than 800 pg/mL; Severely malnourished (as diagnosed by the department's dietitian).